Propanc Biopharma - PPCB Income before deduction of interest, taxes and amortization

Propanc Biopharma Inc (PPCB) is developing proenzyme therapy to eliminate cancer stem cells, leading the market in R&D. Strict climate control during transportation ensures the reliability of the drugs. Insured contracts with carriers guarantee the continuity of trials. The operating profit trend demonstrates the company's actual earnings, with the parameter reaching 0.00.

This indicator measures real cash flow from operating activities, excluding non-cash asset revaluations to verify the issuer's fundamental stability. By analyzing the trend of operating profit before interest and taxes, investors assess the ability of Propanc Biopharma Inc (PPCB) to monetize its unique proenzyme technology, which is critical for exercising pricing power within the inelastic demand segment for targeted cancer therapy.